Cargando…

Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency

BACKGROUND: We studied whether endothelin receptor antagonist and calcimimetic treatments influence renal damage and kidney renin-angiotensin (RA) components in adenine-induced chronic renal insufficiency (CRI). METHODS: Male Wistar rats (n = 80) were divided into 5 groups for 12 weeks: control (n =...

Descripción completa

Detalles Bibliográficos
Autores principales: Törmänen, Suvi, Pörsti, Ilkka, Lakkisto, Päivi, Tikkanen, Ilkka, Niemelä, Onni, Paavonen, Timo, Mustonen, Jukka, Eräranta, Arttu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659028/
https://www.ncbi.nlm.nih.gov/pubmed/29078759
http://dx.doi.org/10.1186/s12882-017-0742-z
_version_ 1783274102170058752
author Törmänen, Suvi
Pörsti, Ilkka
Lakkisto, Päivi
Tikkanen, Ilkka
Niemelä, Onni
Paavonen, Timo
Mustonen, Jukka
Eräranta, Arttu
author_facet Törmänen, Suvi
Pörsti, Ilkka
Lakkisto, Päivi
Tikkanen, Ilkka
Niemelä, Onni
Paavonen, Timo
Mustonen, Jukka
Eräranta, Arttu
author_sort Törmänen, Suvi
collection PubMed
description BACKGROUND: We studied whether endothelin receptor antagonist and calcimimetic treatments influence renal damage and kidney renin-angiotensin (RA) components in adenine-induced chronic renal insufficiency (CRI). METHODS: Male Wistar rats (n = 80) were divided into 5 groups for 12 weeks: control (n = 12), 0.3% adenine (Ade; n = 20), Ade + 50 mg/kg/day sitaxentan (n = 16), Ade + 20 mg/kg/day cinacalcet (n = 16), and Ade + sitaxentan + cinacalcet (n = 16). Blood pressure (BP) was measured using tail-cuff, kidney histology was examined, and RA components measured using RT-qPCR. RESULTS: Adenine caused tubulointerstitial damage with severe CRI, anemia, hyperphosphatemia, 1.8-fold increase in urinary calcium excretion, and 3.5-fold and 18-fold increases in plasma creatinine and PTH, respectively. Sitaxentan alleviated tubular atrophy, while sitaxentan + cinacalcet combination reduced interstitial inflammation, tubular dilatation and atrophy in adenine-rats. Adenine diet did not influence kidney angiotensin converting enzyme (ACE) and AT(4) receptor mRNA, but reduced mRNA of renin, AT(1a), AT(2), (pro)renin receptor and Mas to 40–60%, and suppressed ACE2 to 6% of that in controls. Sitaxentan reduced BP by 8 mmHg, creatinine, urea, and phosphate concentrations by 16–24%, and PTH by 42%. Cinacalcet did not influence BP or creatinine, but reduced PTH by 84%, and increased hemoglobin by 28% in adenine-rats. The treatments further reduced renin mRNA by 40%, while combined treatment normalized plasma PTH, urinary calcium, and increased ACE2 mRNA 2.5-fold versus the Ade group (p < 0.001). CONCLUSIONS: In adenine-induced interstitial nephritis, sitaxentan improved renal function and tubular atrophy. Sitaxentan and cinacalcet reduced kidney renin mRNA by 40%, while their combination alleviated tubulointerstitial damage and urinary calcium loss, and increased kidney tissue ACE2 mRNA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12882-017-0742-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5659028
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56590282017-11-01 Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency Törmänen, Suvi Pörsti, Ilkka Lakkisto, Päivi Tikkanen, Ilkka Niemelä, Onni Paavonen, Timo Mustonen, Jukka Eräranta, Arttu BMC Nephrol Research Article BACKGROUND: We studied whether endothelin receptor antagonist and calcimimetic treatments influence renal damage and kidney renin-angiotensin (RA) components in adenine-induced chronic renal insufficiency (CRI). METHODS: Male Wistar rats (n = 80) were divided into 5 groups for 12 weeks: control (n = 12), 0.3% adenine (Ade; n = 20), Ade + 50 mg/kg/day sitaxentan (n = 16), Ade + 20 mg/kg/day cinacalcet (n = 16), and Ade + sitaxentan + cinacalcet (n = 16). Blood pressure (BP) was measured using tail-cuff, kidney histology was examined, and RA components measured using RT-qPCR. RESULTS: Adenine caused tubulointerstitial damage with severe CRI, anemia, hyperphosphatemia, 1.8-fold increase in urinary calcium excretion, and 3.5-fold and 18-fold increases in plasma creatinine and PTH, respectively. Sitaxentan alleviated tubular atrophy, while sitaxentan + cinacalcet combination reduced interstitial inflammation, tubular dilatation and atrophy in adenine-rats. Adenine diet did not influence kidney angiotensin converting enzyme (ACE) and AT(4) receptor mRNA, but reduced mRNA of renin, AT(1a), AT(2), (pro)renin receptor and Mas to 40–60%, and suppressed ACE2 to 6% of that in controls. Sitaxentan reduced BP by 8 mmHg, creatinine, urea, and phosphate concentrations by 16–24%, and PTH by 42%. Cinacalcet did not influence BP or creatinine, but reduced PTH by 84%, and increased hemoglobin by 28% in adenine-rats. The treatments further reduced renin mRNA by 40%, while combined treatment normalized plasma PTH, urinary calcium, and increased ACE2 mRNA 2.5-fold versus the Ade group (p < 0.001). CONCLUSIONS: In adenine-induced interstitial nephritis, sitaxentan improved renal function and tubular atrophy. Sitaxentan and cinacalcet reduced kidney renin mRNA by 40%, while their combination alleviated tubulointerstitial damage and urinary calcium loss, and increased kidney tissue ACE2 mRNA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12882-017-0742-z) contains supplementary material, which is available to authorized users. BioMed Central 2017-10-27 /pmc/articles/PMC5659028/ /pubmed/29078759 http://dx.doi.org/10.1186/s12882-017-0742-z Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Törmänen, Suvi
Pörsti, Ilkka
Lakkisto, Päivi
Tikkanen, Ilkka
Niemelä, Onni
Paavonen, Timo
Mustonen, Jukka
Eräranta, Arttu
Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency
title Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency
title_full Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency
title_fullStr Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency
title_full_unstemmed Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency
title_short Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency
title_sort endothelin a receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659028/
https://www.ncbi.nlm.nih.gov/pubmed/29078759
http://dx.doi.org/10.1186/s12882-017-0742-z
work_keys_str_mv AT tormanensuvi endothelinareceptorblockerandcalcimimeticintheadenineratmodelofchronicrenalinsufficiency
AT porstiilkka endothelinareceptorblockerandcalcimimeticintheadenineratmodelofchronicrenalinsufficiency
AT lakkistopaivi endothelinareceptorblockerandcalcimimeticintheadenineratmodelofchronicrenalinsufficiency
AT tikkanenilkka endothelinareceptorblockerandcalcimimeticintheadenineratmodelofchronicrenalinsufficiency
AT niemelaonni endothelinareceptorblockerandcalcimimeticintheadenineratmodelofchronicrenalinsufficiency
AT paavonentimo endothelinareceptorblockerandcalcimimeticintheadenineratmodelofchronicrenalinsufficiency
AT mustonenjukka endothelinareceptorblockerandcalcimimeticintheadenineratmodelofchronicrenalinsufficiency
AT erarantaarttu endothelinareceptorblockerandcalcimimeticintheadenineratmodelofchronicrenalinsufficiency